There is a better way — moving beyond the patents vs access debate: A Guest commentary
Gilead’s strategy for access to HIV, HCV drugs in low-income countries holds lessons for COVID-19 vaccines
Ex-Gilead execs Clifford Samuel and Claudio Lilienfeld propose a middle ground in the IP waiver debate based on Gilead’s solutions to getting HIV and HCV therapies to patients in low-income countries.
The debate about whether to suspend patent rights for COVID vaccines doesn’t need to be an “us vs. them” battle that pits access against innovation. Drawing on our previous work for Gilead, we propose a scenario that can create a win for patients, companies and countries.
We are currently in the throes of the latest iteration of a global debate about patent rights